Therapeutic potential of endothelial progenitor cells for cardiovascular diseases.
Therapeutic potential of endothelial progenitor cells for cardiovascular diseases.
复制标题
DOI：
10.2174/157016106775203063
复制
发表时间：
2006
影响因子：
4.5
通讯作者：
Lijing Jia;Masafumi Takahashi;T. Yoshioka;H. Morimoto;H. Ise;Uichi Ikeda
中科院分区：
文献类型：
--
作者：
Lijing Jia;Masafumi Takahashi;T. Yoshioka;H. Morimoto;H. Ise;Uichi Ikeda
在过去的十年中，研究人员已经从成年动物和人类的各种组织中定义了定向干细胞或祖细胞，包括骨髓，外周血，脑，肝脏和生殖器官。最近，内皮祖细胞（EPCs）从外周血单个核细胞中分离出来，并被证明是纳入新血管形成的病灶。这一发现，循环EPCs可能回家到网站的新生血管和分化成成熟的内皮细胞原位与“血管生成”的概念是一致的，并表明，血管生成和血管生成可能构成出生后新生血管形成的互补机制。此外，缺血性心血管疾病的实验和临床研究表明，EPC移植的治疗潜力。本文就内皮祖细胞的生物学特性及其在心血管疾病治疗中的应用前景作一综述。
In the past decade, researchers have defined committed stem or progenitor cells from various tissues, including bone marrow, peripheral blood, brain, liver and reproductive organs, in both adult animals and humans. Recently, endothelial progenitor cells (EPCs) were isolated from peripheral blood mononuclear cells and were shown to be incorporated into foci of neovascularization. This finding that circulating EPCs may home into sites of neovascularization and differentiate into mature endothelial cells in situ is consistent with the concept of 'vasculogenesis' and suggests that vasculogenesis and angiogenesis might constitute complementary mechanisms for postnatal neovascularization. Furthermore, experimental and clinical studies on ischemic cardiovascular diseases suggest a therapeutic potential for EPC transplantation. In this review, we summarize the biological features of EPCs and discuss their therapeutic potential for the treatment of cardiovascular diseases.